.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The EOLIA randomized trial evaluated early venovenous extracorporeal membrane oxygenation in patients with very severe acute respiratory distress syndrome. The trial did not demonstrate a statistically significant reduction in the primary endpoint of 60-day mortality, although mortality was numerically lower with ECMO and a substantial proportion of patients in the control group crossed over to rescue ECMO. This makes the study especially valuable for clinical decision-making because it illustrates both the potential benefit and the complexity of evaluating rescue therapies in critical illness. ECMO should therefore not be treated as a routine escalation step for all patients with severe hypoxaemia. Instead, selection, timing, referral, center expertise, and integration with lung-protective ventilation and prone positioning are crucial. For HCPs, the practical takeaway is that ECMO is best considered within a structured severe-ARDS pathway, with early recognition of patients whose trajectory is deteriorating and timely consultation with an experienced center. This evidence fits the conference’s focus on ECMO capacity-building beyond metro centres and on realistic referral networks for complex respiratory failure.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The EOLIA randomized trial evaluated early venovenous extracorporeal membrane oxygenation in patients with very severe acute respiratory distress syndrome. The trial did not demonstrate a statistically significant reduction in the primary endpoint of 60-day mortality, although mortality was numerically lower with ECMO and a substantial proportion of patients in the control group crossed over to rescue ECMO. This makes the study especially valuable for clinical decision-making because it illustrates both the potential benefit and the complexity of evaluating rescue therapies in critical illness. ECMO should therefore not be treated as a routine escalation step for all patients with severe hypoxaemia. Instead, selection, timing, referral, center expertise, and integration with lung-protective ventilation and prone positioning are crucial. For HCPs, the practical takeaway is that ECMO is best considered within a structured severe-ARDS pathway, with early recognition of patients whose trajectory is deteriorating and timely consultation with an experienced center. This evidence fits the conference’s focus on ECMO capacity-building beyond metro centres and on realistic referral networks for complex respiratory failure.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
